Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

(2014) Alice Laroni et al.   BMC Neurology

The autonomic balance predicts cardiac responses after the first dose of fingolimod

(2014) S Rossi et al.   Multiple Sclerosis Journal

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

(2013) Ralf Gold et al.   JOURNAL OF NEUROLOGY

Early tolerability and safety of fingolimod in clinical practice

(2012) Daniel Ontaneda et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Placebo-controlled study of the effects of fingolimod on cardiac rate and rhythm and pulmonary function in healthy volunteers

(2011) Robert Schmouder et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE